GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients

Metabolomics has recently undergone rapid development; however, metabolomic analysis in cerebrospinal fluid (CSF) is not a common practice. We analyzed the metabolite profiles of preoperative CSF samples from 32 patients with histologically confirmed glioma using gas chromatography/mass spectrometry (GC/MS). We assessed how alterations in the metabolite levels were related to the World Health Organization (WHO) tumor grades, tumor location, gadolinium enhancement on magnetic resonance imaging (MRI), and the isocitrate dehydrogenase (IDH) mutation status. Sixty-one metabolites were identified in the CSF from glioma patients using targeted, quantitative and non-targeted, semi-quantitative analysis. The citric and isocitric acid levels were significantly higher in the glioblastoma (GBM) samples than in the grades I–II and grade III glioma samples. In addition, the lactic and 2-aminopimelic acid levels were relatively higher in the GBM samples than in the grades I–II glioma samples. The CSF levels of the citric, isocitric, and lactic acids were significantly higher in grade I–III gliomas with mutant IDH than in those with wild-type IDH. The tumor location and enhancement obtained using MRI did not significantly affect the metabolite profiles. Higher CSF levels of lactic acid were statistically associated with a poorer prognosis in grades III–IV malignant gliomas. Our study suggests that the metabolomic analysis of CSF from glioma patients may be useful for predicting the glioma grade, metabolic state, and prognosis of gliomas.

[1]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[2]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[3]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[4]  D. Wishart,et al.  The human cerebrospinal fluid metabolome. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  G. Webb,et al.  Annual Reports on NMR Spectroscopy , 2002 .

[6]  M. Buckland,et al.  Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications , 2011, Journal of Clinical Pathology.

[7]  Soonmee Cha,et al.  Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma , 2009, Journal of Neuro-Oncology.

[8]  Webster K. Cavenee,et al.  WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .

[9]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[10]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[11]  J. M. Argiles,et al.  The metabolic environment of cancer , 1988, Molecular and Cellular Biochemistry.

[12]  S. Wijmenga,et al.  Quantitative Proteomics and Metabolomics Analysis of Normal Human Cerebrospinal Fluid Samples* , 2010, Molecular & Cellular Proteomics.

[13]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[14]  H. Weiner,et al.  Germ cell tumors of the CNS in children: recent advances in therapy , 1999, Child's Nervous System.

[15]  A. von Deimling,et al.  Detection of 2‐Hydroxyglutarate in Formalin‐Fixed Paraffin‐Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry , 2012, Brain pathology.

[16]  Y. Yamazaki,et al.  PRIMARY BIOMARKERS IN CEREBRAL SPINAL FLUID OBTAINED FROM PATIENTS WITH INFLUENZA-ASSOCIATED ENCEPHALOPATHY ANALYZED BY METABOLOMICS , 2006, The International journal of neuroscience.

[17]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[18]  E. Kohmura,et al.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). , 2012, Neuro-oncology.

[19]  Yuji Akiyama,et al.  Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. , 2011, Neuro-oncology.

[20]  T. Cloughesy,et al.  Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. , 2012, Neuro-oncology.

[21]  T. Takenawa,et al.  Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography–mass spectrometry , 2011, Journal of Gastroenterology.

[22]  Jos H Beijnen,et al.  Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. , 2008, Current clinical pharmacology.

[23]  L. Cantley,et al.  Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma* , 2012, Molecular & Cellular Proteomics.

[24]  Frank Suits,et al.  The impact of delayed storage on the measured proteome and metabolome of human cerebrospinal fluid. , 2011, Clinical chemistry.

[25]  P. Andersen,et al.  Disease-Related Changes in the Cerebrospinal Fluid Metabolome in Amyotrophic Lateral Sclerosis Detected by GC/TOFMS , 2011, PloS one.

[26]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[27]  Y. Oda,et al.  Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. , 2009, Analytical chemistry.

[28]  H. Busch,et al.  Citrate accumulation in slices of transplantable tumors of the rat. , 1957, Cancer research.

[29]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[30]  R. Lenkinski,et al.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. , 2006, AJNR. American journal of neuroradiology.

[31]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[32]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[33]  S. Hajdu.  Pilocytic Astrocytoma , 2004, Acta Cytologica.

[34]  T. Takenawa,et al.  GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis , 2011, Inflammation Research.

[35]  M. Brada.  Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[36]  E. Fukusaki,et al.  Serum metabolomics as a novel diagnostic approach for pancreatic cancer , 2010, Metabolomics.

[37]  L. Liotta,et al.  CSF proteome: a protein repository for potential biomarker identification , 2005, Expert review of proteomics.

[38]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[39]  Bertrand Audoin,et al.  Inflammatory Multiple-Sclerosis Plaques Generate Characteristic Metabolic Profiles in Cerebrospinal Fluid , 2007, PloS one.

[40]  A. Panigrahy,et al.  Citrate in Pediatric CNS Tumors? , 2008, American Journal of Neuroradiology.

[41]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[42]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[43]  E. Fukusaki,et al.  Practical non-targeted gas chromatography/mass spectrometry-based metabolomics platform for metabolic phenotype analysis. , 2011, Journal of bioscience and bioengineering.

[44]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[45]  O. Chinot,et al.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas , 2012, Journal of Neuro-Oncology.

[46]  John C. Lindon,et al.  NMR Spectroscopy of Biofluids , 1999 .

[47]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[48]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[50]  M. Tomita,et al.  Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. , 2009, Cancer research.

[51]  Lutgarde M. C. Buydens,et al.  Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis , 2011, BMC Bioinformatics.

[52]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[53]  F. Gilles,et al.  Elevated citrate in pediatric astrocytomas with malignant progression. , 2011, Neuro-oncology.

[54]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[55]  J. Hornegger,et al.  Neurochemical dementia diagnostics: assays in CSF and blood , 2008, European Archives of Psychiatry and Clinical Neuroscience.